Meijer et al. showed improved oncological outcomes for patients who received pre-SRT PSMA PET/CT in biochemically recurrent prostate cancer: patients without PSMA PET/CT had a biochemical progression rate of 21% after one year, compared to 8% with pre-SRT PSMA PET/CT [26]. The gene discussed is FOLH1; the disease is prostate cancer.